OVERVIEW

Community Practice Connections™: Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma will be invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Community Practice Connections™: Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting consists of a series of interactive clinical vignettes, short video interviews with leading experts in renal cell carcinoma (RCC), and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Substantiate treatment decisions across multidisciplinary teams for patients with early-stage renal cell carcinoma (RCC) based on the most pertinent clinical trial evidence for targeted therapy.
• Integrate knowledge of patient selection for adjuvant therapy in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs adjuvant treatment in the care of patients with RCC.
• Manage treatment-related toxicities as a component of therapeutic decision making in adjuvant treatment settings for patients with RCC.
• Evaluate recent clinical trial data, key ongoing trials, and how emerging adjuvant strategies may further impact the RCC treatment landscape.